Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:5602 |
Name | T-cell adult acute lymphocytic leukemia |
Definition | An adult acute lymphocytic leukemia occurring in adults and that has_material_basis_in T cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute lymphoblastic leukemia adult acute lymphocytic leukemia T-cell adult acute lymphocytic leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FBXW7 R465H | MRK-003 | T-cell adult acute lymphocytic leukemia | resistant | detail... |
FBXW7 del | MRK-003 | T-cell adult acute lymphocytic leukemia | resistant | detail... |
FBXW7 R505C | MRK-003 | T-cell adult acute lymphocytic leukemia | resistant | detail... |
FBXW7 R479Q | MRK-003 | T-cell adult acute lymphocytic leukemia | resistant | detail... |
FBXW7 R465C | MRK-003 | T-cell adult acute lymphocytic leukemia | resistant | detail... |
FBXW7 R505L | MRK-003 | T-cell adult acute lymphocytic leukemia | resistant | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01363817 | Phase I | Dexamethasone BMS-906024 | Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | Completed | USA | FRA | DEU | 0 |
NCT02763384 | Phase II | BKT140 + Nelarabine | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma | Terminated | USA | 0 |
NCT02999633 | Phase II | Isatuximab | Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia (ISLAY) | Terminated | USA | LTU | ITA | HUN | FRA | FIN | 1 |
NCT05519527 | Phase I | STI-6129 | A Phase 1, Open-Label, Dose-Escalation Study of Safety And Efficacy of An Anti-CD38 Antibody Drug Conjugate (STI-6129) In Patients With Relapsed Or Refractory T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) Or Acute Myeloid Leukemia (AML) | Withdrawn | 0 |